An Analysis of the Benefit of Using HEV Genotype 3 Antigens in Detecting Anti-HEV IgG in a European Population

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Schnegg, Annatina ^a   Bürgisser, Philippe ^b   André, Cyril ^b   Kenfak Foguena, Alain ^b   Canellini, Giorgia ^c   Moradpour, Darius ^b   Abravanel, Florence ^d   Izopet, Jacques ^d   Cavassini, Matthias ^b   Darling, Katharine E A ^b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c Service Regional Vaudois de Transfusion Sanguine   (Switzerland)

^d CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS E VIRUS ANTIGEN; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ADULT; ARTICLE; BLOOD DONOR; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; FRANCE; GENOTYPE; HEPATITIS E; HUMAN; IMMUNOASSAY; IMMUNODOT ASSAY; INTERMETHOD COMPARISON; MALE; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; SEROLOGY TEST KIT; SEROPREVALENCE; SWITZERLAND;

ADULT; ANTIGENS, VIRAL; ASYMPTOMATIC DISEASES; BLOOD DONORS; EUROPE; FEMALE; GENOTYPE; HEPATITIS E; HEPATITIS E VIRUS; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN G; MALE; MIDDLE AGED;

EID: 84877154849     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062980     Document Type: Article

References (21)

1. Kamar N, Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, et al. (2012) Hepatitis E. Lancet. 379: 2477-2488.
2. Herremans M, Bakker J, Duizer E, Vennema H, Koopmans MP, (2007) Use of serological assays for diagnosis of hepatitis E virus genotype 1 and 3 infections in a setting of low endemicity. Clin Vaccine Immunol 14: 562-568.
3. Clemente-Casares P, Pina S, Buti M, Jardi R, MartIn M, et al. (2003) Hepatitis E virus epidemiology in industrialized countries. Emerg Infect Dis 9: 448-454.
4. Turner J, Godkin A, Neville P, Kingham J, Ch'ng CL, (2010) Clinical characteristics of hepatitis E in a "Non-Endemic" population. J Med Virol 82: 1899-1902.
5. Aggarwal R, (2011) Clinical presentation of hepatitis E. Virus Res. 161: 15-22.
6. Khudyakov Y, Kamili S, (2011) Serological diagnostics of hepatitis E virus infection. Virus Res 161: 84-92.
7. Mitsui T, Tsukamoto Y, Suzuki S, Yamazaki C, Masuko K, et al. (2005) Serological and molecular studies on subclinical hepatitis E virus infection using periodic serum samples obtained from healthy individuals. J Med Virol 76: 526-533.
8. Bigaillon C, Tesse S, Lagathu G, Nicand E, (2010) Use of hepatitis E IgG avidity for diagnosis of hepatitis E infection. J Virol Methods 164: 127-130.
9. Mast EE, Alter MJ, Holland PV, Purcell RH, (1998) Evaluation of assays for antibody to hepatitis E virus by a serum panel. Hepatitis E Virus Antibody Serum Panel Evaluation Group. Hepatology 27: 857-861.
10. Dalekos GN, Zervou E, Elisaf M, Germanos N, Galanakis E, et al. (1998) Antibodies to hepatitis E virus among several populations in Greece: increased prevalence in an hemodialysis unit. Transfusion 38: 589-595.
11. Kaufmann A, Kenfak-Foguena A, Andre C, Canellini G, Burgisser P, et al. (2011) Hepatitis E virus seroprevalence among blood donors in southwest Switzerland. PLoS One 6: e21150.
12. Mansuy JM, Bendall R, Legrand-Abravanel F, Saune K, Miedouge M, et al. (2011) Hepatitis E virus antibodies in blood donors, France. Emerg Infect Dis 17: 2309-2312.
13. Abravanel F, Sandres-Saune K, Lhomme S, Dubois M, Mansuy JM, et al. (2012) Genotype 3 diversity and quantification of hepatitis E virus RNA. J Clin Microbiol 50: 897-902.
14. Lin CC, Wu JC, Chang TT, Chang WY, Yu ML, et al. (2000) Diagnostic value of immunoglobulin G (IgG) and IgM anti-hepatitis E virus (HEV) tests based on HEV RNA in an area where hepatitis E is not endemic. J Clin Microbiol 38: 3915-3918.
15. Yarbough PO, Tam AW, Fry KE, Krawczynski K, McCaustland KA, et al. (1991) Hepatitis E virus: identification of type-common epitopes. J Virol 65: 5790-5797.
16. Bendall R, Ellis V, Ijaz S, Ali R, Dalton H, (2010) A comparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries. J Med Virol 82: 799-805.
17. Li RC, Ge SX, Li YP, Zheng YJ, Nong Y, et al. (2006) Seroprevalence of hepatitis E virus infection, rural southern People's Republic of China. Emerg Infect Dis 12: 1682-1688.
18. Zhang JZ, Im SW, Lau SH, Chau TN, Lai ST, et al. (2002) Occurrence of hepatitis E virus IgM, low avidity IgG serum antibodies, and viremia in sporadic cases of non-A,-B, and-C acute hepatitis. J Med Virol 66: 40-48.
19. Kenfak-Foguena A, Schoni-Affolter F, Burgisser P, Witteck A, Darling KE, et al. (2011) Hepatitis E Virus seroprevalence and chronic infections in patients with HIV, Switzerland. Emerg Infect Dis 17: 1074-1078.
20. Kamar N, Selves J, Mansuy JM, Ouezzani L, Peron JM, et al. (2008) Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 358: 811-817.
21. Christensen PB, Engle RE, Hjort C, Homburg KM, Vach W, et al. (2008) Time trend of the prevalence of hepatitis E antibodies among farmers and blood donors: a potential zoonosis in Denmark. Clin Infect Dis 47: 1026-1031.